Sugi Predict

Sugi Predict / Compounds / SCHEMBL851969

SCHEMBL851969

SCHEMBL851969

COC(=O)c1cc(OC)cc(OC)c1C=O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ERN1 O75460 1/20 0.60
▸ LMNA P02545 1/20 0.56
▸ ABCG2 Q9UNQ0 1/20 0.46
▸ GAA P10253 4/20 0.46
▸ ALDH1A1 P00352 4/20 0.46
▸ HTT P42858 1/20 0.46
▸ KDM4E B2RXH2 6/20 0.45
▸ CYP1A2 P05177 1/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ GLA P06280 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ POLB P06746 3/20 0.43
▸ POLK Q9UBT6 1/20 0.42
▸ POLH Q9Y253 1/20 0.42
▸ CHRNA7 P36544 1/20 0.42
▸ MAOA P21397 2/20 0.41
▸ HPGD P15428 1/20 0.41
▸ MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4370908 0.90 KDM4E (0.49) ERN1LMNAGAAALDH1A1HTT
SCHEMBL4845911 0.85 ERN1 (0.62) ERN1LMNAABCG2ALDH1A1KDM4E
SCHEMBL4833961 0.83 ERN1 (0.60) ERN1LMNAGAAALDH1A1KDM4E
SCHEMBL21973226 0.83 FLT3 (0.47) ERN1LMNAGAAALDH1A1HTT
SCHEMBL4833900 0.82 ERN1 (0.41) ERN1LMNAGAAALDH1A1HTT
2,4,6-Trimethoxybenzaldehyde SCHEMBL28687256 0.80 ERN1 (0.75) ERN1LMNAABCG2ALDH1A1KDM4E
2,4,6-Trimethoxybenzaldehyde SCHEMBL34873 0.80 ERN1 (0.74) ERN1LMNAABCG2ALDH1A1KDM4E
SCHEMBL205044 0.79 KDM4E (0.50) LMNAGAAALDH1A1HTTKDM4E
2,4,6-Trimethoxybenzaldehyde SCHEMBL28687257 0.78 ERN1 (0.71) ERN1LMNAABCG2ALDH1A1KDM4E
SCHEMBL24379065 0.77 GAA (0.54) ABCG2GAAALDH1A1HTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060084176-A1 Detection of uronium salts YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2006-04-20 — — US claimed
CN-109988156-B Aminopyrimidine compound 广东中科药物研究有限公司 2021-12-28 — — CN disclosed
US-20200140450-A1 CHEMICAL METHOD OF PRODUCING SMTP GROUPS OR SMTP-7 AND INTERMEDIATES USED IN THE METHOD SHOWA UNIVERSITY (JP) 2020-05-07 — — US disclosed
US-20180346484-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF ABBVIE DEUTSCHLAND (DE) 2018-12-06 — — US disclosed
US-9879033-B2 Modulators of 5-HT receptors and methods of use thereof AbbVie Deutschland GmbH & Co. KG (DE) 2018-01-30 — — US disclosed
EP-2794620-B1 BODIPY STRUCTURE FLUORESCENCE PROBES FOR DIVERSE BIOLOGICAL APPLICATIONS NAT UNIV SINGAPORE (SG) 2017-11-15 — — EP disclosed
EP-2571353-B1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF ABBVIE INC (US) 2017-08-09 — — EP disclosed
US-9423396-B2 Bodipy structure fluorescence probes for diverse biological applications NATIONAL UNIVERSITY OF SINGAPORE (SG) 2016-08-23 — — US disclosed
US-9423396-B2 Bodipy structure fluorescence probes for diverse biological applications NATIONAL UNIVERSITY OF SINGAPORE (SG) 2016-08-23 — — US disclosed
US-20160096851-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF ABBVIE INC. 2016-04-07 — — US disclosed
EP-2044036-A1 [4,5']BIPYRIMIDINYL-6,4'-DIAMINE DERIVATIVES AS PROTEIN KINASE INHBITORS IRM, LLC (BM) 2009-04-08 — — EP disclosed
US-7423030-B2 1-amino-phthalazine derivatives, the preparation and the therapeutic use thereof SANOFI-AVENTIS (FR) 2008-09-09 — — US disclosed
US-20080064037-A1 RNA-SELECTIVE PROBES FOR LIVE CELL IMAGING OF NUCLEAR STRUCTURE AND FUNCTION NEW YORK UNIVERSITY (US) 2008-03-13 — — US disclosed
US-20080064037-A1 RNA-SELECTIVE PROBES FOR LIVE CELL IMAGING OF NUCLEAR STRUCTURE AND FUNCTION NEW YORK UNIVERSITY (US) 2008-03-13 — — US disclosed
WO-2008008747-A1 [4,5']BIPYRIMIDINYL-6,4'-DIAMINE DERIVATIVES AS PROTEIN KINASE INHBITORS IRM LLC (BM) 2008-01-17 — — WO disclosed
WO-2008008747-A1 [4,5']BIPYRIMIDINYL-6,4'-DIAMINE DERIVATIVES AS PROTEIN KINASE INHBITORS IRM LLC (BM) 2008-01-17 — — WO disclosed
US-20070099895-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2007-05-03 — — US disclosed
US-20060084176-A1 Detection of uronium salts YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2006-04-20 — — US disclosed
US-6776830-B2 CONTAINS POLYSACCHARIDE; GIVES RELIABLE PERFORMANCE YIELDING RAPIDLY DRYING IMAGES SEIKO EPSON CORPORATION (JP) 2004-08-17 — — US disclosed
US-20020185038-A1 Aqueous ink composition for use in an ink-jet printer SEIKO EPSON CORPORATION 2002-12-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064037-A1 RNA-SELECTIVE PROBES FOR LIVE CELL IMAGING OF NUCLEAR STRUCTURE AND FUNCTION SNRPE, HNRNPUL2, EFTUD2 ERN1 157/4885LMNA 466/4885ABCG2 2251/4885
US-20160096851-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF HTR3A, HTR5A, HTR3C ERN1 4806/4885LMNA 4501/4885ABCG2 299/4885
US-20180346484-A1 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF HTR3A, HTR5A, HTR3C ERN1 4806/4885LMNA 4501/4885ABCG2 299/4885
US-20070099895-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF CYP11B2, CYP11B1, GOT2 ERN1 4772/4885LMNA 2581/4885ABCG2 508/4885
US-20200140450-A1 CHEMICAL METHOD OF PRODUCING SMTP GROUPS OR SMTP-7 AND INTERMEDIATES USED IN THE METHOD TST, SMS, TMSB4X ERN1 1906/4885LMNA 1028/4885ABCG2 3999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.